baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Argen X NV/ NL0010832176 /

9/5/2024 8:52:14 PM	Chg. -	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
525.6012USD	-	61 Turnover: 32,277.6552	-Bid Size: -	-Ask Size: -	33.82 bill.USD	-	-

GlobeNewswire 8/28 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 7/25 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

GlobeNewswire 7/18 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...

GlobeNewswire 7/16 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...

GlobeNewswire 6/25 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...

GlobeNewswire 6/21 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...

GlobeNewswire 6/17 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...

GlobeNewswire 6/4 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 5/9 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/7 argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire 5/7 argenx to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire 5/2 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

GlobeNewswire 4/16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 3/27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 3/26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 3/26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 3/7 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 2/29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 2/26 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 2/22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 2/20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

GlobeNewswire 1/18 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...

GlobeNewswire 1/8 argenx Highlights 2024 Strategic Priorities

GlobeNewswire 1/2 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 11/28/2023 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...

Argen X NV/ NL0010832176 /

If you wish to receive reply to your feedback, please provide your email address.